My personal question: What will come first, M&A activity or the drug monograph? I ask this because we don't have to wait for a drug monograph from the FDA for ANY type of M&A, including M&A activity with their global pharma partner. With that said, anything could happen now at any time.
OH, ps: Congratulation to the LABS team on a great quarter, didn't want press *1 on the CC just to say that :-)